Zusammenfassung
Diese Einschätzung wurde am 02.07.18 mit einem Endkurs von 20,02 € beendet. Stark abwärts ging es für die BUY Einschätzung von stratec zu Arsanis mit einer Rendite von -71,97 %. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Arsanis | - | - | - | - |
iShares Core DAX® | 1,66 % | 6,95 % | 18,81 % | 17,55 % |
iShares Nasdaq 100 | 1,26 % | 4,88 % | 23,67 % | 36,21 % |
iShares Nikkei 225® | 0,65 % | 10,01 % | 15,05 % | 9,55 % |
iShares S&P 500 | 1,40 % | 4,35 % | 23,30 % | 38,64 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Arsanis diskutieren
Arsanis Pharmaceuticals: A Revolutionary Approach To Infectious Pathogens
- Arsanis (ASNS -2.9%) initiated with Overweight rating and $23 price target by Piper Jaffray. Initiated with Outperform rating by Cowen.
The company is developing monoclonal antibodies directed against bacteria and viruses.
The key R&D program is ASN100, which is directed against 6 cytotoxins critical to Staphylococcus Aureus pathogenesis.
An independent data review committee will conduct an interim analysis in the first half of 2018 to assess the success probability of the trial as designed (a near-term catalyst).
We are initiating coverage on Arsanis stock with a Buy rating and a price target of $35.